Tiger Brokers

BUZZ-Novavax falls after report FDA demands new trial for COVID vaccine

Reuters
Apr 26, 2025
BUZZ-Novavax falls after report FDA demands new trial for COVID vaccine

** Shares of vaccine maker Novavax NVAX.O fall 6.6% to $6.61 in afternoon trading

** US FDA is asking Novavax to conduct an additional clinical trial for its COVID-19 vaccine, despite previous 90% efficacy results, the Wall Street Journal reports, citing people familiar with the matter

** The request came after appointees under Health Secretary Robert F. Kennedy Jr. intervened in the approval process - WSJ

** Novavax did not immediately respond to a Reuters request for comment

** On Wednesday, NVAX said US FDA asked the company to produce more data on its COVID-19 vaccine if it gets full approval

** Including session's moves, stock down 12.3% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10